Rilpivirine Label Highlights Risk In Patients With Higher HIV Levels, Could Limit Use
This article was originally published in The Pink Sheet Daily
Executive Summary
Lead investigator from Phase III trials says Edurant could be viable option in about half of treatment-naïve patients, points out safety advantages.